|
 Lilly's drug, Lartruvo, is approved for use with FDA-approved
chemotherapy doxorubicin in STS patients who cannot be cured with
radiation or surgery or who have a type of STS for which
chemotherapeutic agent anthracycline is an appropriate treatment.
(http://bit.ly/2e6JNrz)
Soft tissue sarcoma refers to cancers that develop in muscles, fat,
tendons or other soft tissues.
The National Cancer Institute estimates that 12,310 new cases of STS
and nearly 5,000 related deaths are likely to occur in 2016.
The European Medicines Agency last month recommended conditional
marketing approval for the drug in combination with doxorubicin in
the European Union.
[to top of second column] |
Lartruvo has already been granted orphan drug status and
breakthrough therapy status by the U.S. health regulator.
Indianapolis, Indiana-based Lilly's shares were up marginally in
afternoon trading.
(Reporting by Akankshita Mukhopadhyay and Dipika Jain in Bengaluru;
Editing by Maju Samuel)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
